$DYAI

Francisco Trust under agreement dated February 28, 1996 sold $344K of DYAI

Francisco Trust under agreement dated February 28, 1996 sold 172,864 shares of DYADIC INTERNATIONAL INC (DYAI) at an average of $1.99 ($1.80–$2.43, $0.34M total) across 7 trades over 2024-06-06 to 2025-01-07.

Original reporting
SEC EDGAR · Francisco Trust under agreement dated February 28, 1996
Published Jul 6, 2026, 10:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 6, 2026, 10:48 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$DYAI
Neutral
medium confidence
Mentioned
$DYAI
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DYAINeutralLow
01

Why it matters

This is a disclosed insider sale by a 10% owner; it can influence sentiment but does not introduce new operating or financial information.

02

Market read

Traders may monitor DYAI for follow-on insider activity or unusual volume, but the filing alone is unlikely to drive a fundamental repricing.

03

What to watch

The article provides no reason for the sale, no change in company guidance, and no indication of additional insider actions around the same time.

Relevance 4/10Novelty 5/10Timing: today’s SEC Form 4 filing (filed 2026-07-06)

Background

The article is an SEC Form 4 insider transaction disclosure for DYADIC INTERNATIONAL INC (DYAI).

Company-level read

Ticker impact

$DYAINeutralMedium confidence
Context

SEC Form 4 shows 10% owner Francisco Trust sold 172,864 DYAI shares for about $343.8K across seven trades.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or new fundamentals emerge.

Evidence & confidence

The filing is a primary-source insider transaction with modest dollar value and no stated fundamental catalyst; absence of a 10b5-1 plan can increase interpretive sensitivity but does not by itself change business outlook.

Market effects

No sector read-across; this is company-specific insider activity.

None indicated.

None indicated.

Counterpoint

The sales span 2024-06-06 to 2025-01-07, so the filing may reflect routine liquidity rather than a new bearish view.

Key entities

  • DYADIC INTERNATIONAL INC

    Subject of the Form 4 insider transaction disclosure (DYAI).

  • Francisco Trust

    10% owner who sold 172,864 shares in open-market transactions.

Related articles

$DYAIMedAI 8/10

Dyadic International Hits Inflection Point as Product Launches Drive Commercial Shift

Dyadic International (NASDAQ:DYAI) said at the Lytham Partners Spring 2026 Investor Conference that it has shifted from an R&D and licensing focus to a commercial-stage protein and enzyme business. It has launched six products in 12 months and secured global distribution and partner deals, including purchase orders for transferrin. The company expects 2026 to be a launch year and reported nearly $3.5 million in upfront milestone fees from Proliant and Inzymes.

$DYAIMedAI 8/10

Dyadic International, Inc.: Dyadic and Scripps Research Collaborate on Rapid-Response Hantavirus Antibody and Vaccine Development

Dyadic International (NASDAQ: DYAI) said it is collaborating with Scripps Research to evaluate monoclonal antibody and vaccine candidates targeting hantaviruses, including Andes virus, associated with Hantavirus Pulmonary Syndrome. The companies plan to assess Dyadic’s C1 microbial platform for rapid, scalable biologic manufacturing, building on prior Andes work and earlier GMP/Phase 1 C1-produced biologics.